Neonatal dolutegravir met PK targets; the film still needs a real-world test

PETITE-DTG met pharmacokinetic targets in 41 term neonates. Sixteen mothers found the oral film usable, but routine-care and preterm evidence are still missing.

The hot take

A medicine can be pharmacokinetically plausible and easy to give without yet being ready for routine neonatal rollout.

PETITE-DTG supplied the first multidose pharmacokinetic and short-term safety evidence for dolutegravir from birth. In its 41-neonate safety set, both a half dispersible tablet and a 5 mg oral-dispersible film met the prespecified exposure targets. A June 2026 follow-up adds a favorable usability signal for the film, but from only 16 mothers and six staff members in a highly supported trial setting.

What the parent trial tested

At one South African site, eligible infants were term, weighed at least 2 kg, were born to virologically suppressed mothers receiving dolutegravir-based antiretroviral therapy, and were classified as having low acquisition risk. The study drug was added to zidovudine prophylaxis. The research schedule gave dolutegravir 5 mg every 48 hours through day 14, then daily through day 28; this describes the protocol, not a bedside dosing instruction.